LONDON (Reuters) – Japan’s Suntory Beverage & Food Ltd is to buy GlaxoSmithKline Plc’s Lucozade and Ribena brands for 1.35 billion pounds ($2.11 billion) to broaden its soft drinks portfolio and help it expand into new markets.
The acquisition, announced by the companies on Monday, had been widely anticipated since people close to the process said last week that Suntory was in advanced talks on a deal that would pre-empt an auction of the iconic British drinks.
NEW YORK/LONDON (Reuters) – U.S. authorities are investigating British drugmaker GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) for violations of U.S. anti-bribery laws in China after Chinese government officials accused the company of bribing doctors, a company spokesman confirmed on Friday.
The investigation is part of a wider probe of drugmakers’ sales practices in China, said a source familiar with the investigation.
LONDON (Reuters) – Japan’s Suntory Beverage & Food (2587.T: Quote, Profile, Research, Stock Buzz) is in advanced talks to buy GlaxoSmithKline’s (GSK.L: Quote, Profile, Research, Stock Buzz) Lucozade and Ribena drinks for more than 1 billion pounds ($1.6 billion), in a deal that would pre-empt an auction of the brands, two people following the process said.
A deal could be announced in the next few days, one of the sources said on Thursday.
LONDON (Reuters) – An experimental cancer vaccine from GlaxoSmithKline failed to meet the first of two joint targets in a closely watched late-stage clinical trial, dealing a blow to the high-risk, high-reward project.
Britain’s biggest drugmaker said on Thursday that it would continue with the Phase III trial of its MAGE-A3 therapeutic vaccine until the second of the targets, known as co-primary endpoints, is assessed.
AMSTERDAM (Reuters) – Doctors urging heart patients to “keep taking the tablets” would have a more success if they used a new combination medicine known as a polypill, according to research published on Tuesday.
An international trial involving 2,000 patients found a four-in-one pill from Dr. Reddy’s Laboratories Ltd significantly improved adherence compared with asking people to take their tablets individually.
AMSTERDAM, Sept 3 (Reuters) – French riders in the Tour de
France live an average of six years longer than the general
population and die less often of cardiovascular problems,
researchers said, which may help ease worries about the effect
of extreme exercise on the heart.
The research also offered limited assurance that doping was
unlikely to pose a major heart health risk, at least in the
short term, since any major adverse impact would have skewed the
results. Illicit use of the blood-boosting drug EPO, or
erythropoietin, has been rampant in competitive cycling since